Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library

被引：63

作者：

Davis, Rohan A. ^{[2
]}

Innocenti, Alessio ^{[1
]}

Poulsen, Sally-Ann ^{[2
]}

Supuran, Claudiu T. ^{[1
]}

机构：

[1] Univ Florence, Lab Chim Bioinorgan, I-50019 Florence, Italy

[2] Griffith Univ, Eskitis Inst, Nathan, Qld 4111, Australia

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2010年 / 18卷 / 01期

关键词：

Carbonic anhydrase; Natural product; Phenols; Mitochondrial isoforms; Selective enzyme inhibitors; PLANT ENDIANDRA-ANTHROPOPHAGORUM; X-RAY; STRUCTURE ELUCIDATION; MASS-SPECTROMETRY; SALICYLIC-ACID; GENUS XYLARIA; XIV; MICROFUNGUS; SULFONAMIDE; TARGET;

D O I：

10.1016/j.bmc.2009.11.021

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

We have investigated the enzyme inhibition characteristics of a natural product (NP)-based phenolic library against a panel of human carbonic anhydrases (hCAs, EC 4.2.1.1) which included hCAs I and II (cytosolic) and hCA VA/VB (mitochondrial isoforms). Most of these compounds were weak, micromolar inhibitors of the two cytosolic hCAs (K(I)s > 10 mu M) but showed good hCA VA/VB inhibitory activity with inhibition constants in the range of 70-125 nM. The selectivity ratios for inhibiting the mitochondrial over the cytosolic isoforms for these phenol derivatives were in the range of 120-3800, making them the most isoform-selective compounds for inhibiting hCA VA/VB known to date. The CA VA/VB enzymes are involved in biosynthetic processes such as gluconeogenesis, lipogenesis and ureagenesis, and no pharmacological inhibitors with good selectivity are currently available. Thus the NP inhibitors identified during these studies are excellent leads for obtaining even more effective compounds that selectively target mitochondrial hCAs, and also have the potential to be used as tools for understanding the physiological processes that are regulated by the two mitochondrial CA isoforms. (C) 2009 Elsevier Ltd. All rights reserved.

引用

下载

页码：14 / 18

页数：5

共 50 条

[21] Carbonic anhydrase inhibitors. Synthesis, molecular structures, and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with novel 3-pyridinesulfonamide derivatives
Brzozowski, Zdzislaw
Slawinski, Jaroslaw
Gdaniec, Maria
Innocenti, Alessio
Supuran, Claudiu T.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (09) : 4403 - 4410
[22] Carbonic anhydrase inhibitors:: Synthesis and inhibition of cytosolic membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties
Winum, JY
Dogné, JM
Casini, A
de Leval, X
Montero, JL
Scozzafava, A
Vullo, D
Innocenti, A
Supuran, CT
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 2121 - 2125
[23] Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors
Winum, JY
Vullo, D
Casini, A
Montero, JL
Scozzafava, A
Supuran, CT
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (11) : 2197 - 2204
[24] Carbonic anhydrase inhibitors. Synthesis of heterocyclic 4-substituted pyridine-3-sulfonamide derivatives and their inhibition of the human cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII
Slawinski, Jaroslaw
Szafranski, Krzysztof
Vullo, Daniela
Supuran, Claudiu T.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 69 : 701 - 710
[25] Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII
Slawinski, Jaroslaw
Pogorzelska, Aneta
Zolnowska, Beata
Brozewicz, Kamil
Vullo, Daniela
Supuran, Claudiu T.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 82 : 47 - 55
[26] Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX
Garaj, V
Puccetti, L
Fasolis, G
Winum, JY
Montero, JL
Scozzafava, A
Vullo, D
Innocenti, A
Supuran, CT
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (12) : 3102 - 3108
[27] Carbonic anhydrase inhibitors: Inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic Isozymes I and II with aliphatic sulfamates
Winum, JY
Vullo, D
Casini, A
Montero, JL
Scozzafava, A
Supuran, CT
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) : 5471 - 5477
[28] QSAR studies of sulfamate and sulfamide inhibitors targeting human carbonic anhydrase isozymes I, II, IX and XII
Tarko, Laszlo
Supuran, Claudiu T.
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (06) : 1404 - 1409
[29] Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX
Turkmen, H
Durgun, M
Yilmaztekin, S
Emul, M
Innocenti, A
Vullo, D
Scozzafava, A
Supuran, CT
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) : 367 - 372
[30] Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide
Cecchi, A
Winum, JY
Innocenti, A
Vullo, D
Montero, JL
Scozzafava, A
Supuran, CT
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (23) : 5775 - 5780

← 1 2 3 4 5 →